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TRAIL (TNF-related apoptosis-inducing ligand) is a potential anticancer agent because of its tumor-specifc 
apoptosis inducer activity without scathing normal cells. MicroRNAs (miRNAs) emerge as important regulators 
of cell viability. Our recent studies showed that miR-7 is a potential sensitizer for TRAIL-induced apoptosis in 
glioblastoma (GBM) cells, and XIAP is a critical gene in the apoptotic process as a direct downstream gene of 
miR-7. Additionally, this regulatory axis could also exert in other types of tumor cells. More importantly, we 
confirmed that co-delivery of sTRAIL and tumor suppressor miR-7 by MSCs leads to synergistic cancer killing 
effect. Thus, miR-7 has been demonstrated to be a critical sensitizer for TRAIL-induced apoptosis through 
regulating XIAP and highlights a novel therapeutic strategy for the treatment of GBM. 
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Introduction 
Glioblastoma multiforme (GBM) is still one of the most 
lethal forms of brain tumor despite of the improvements in 
treatments. Tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) gained much attention 
during the past decade due to its therapeutic potential as a 
tumor-specific apoptosis inducer without affecting normal 
cells [1, 2]. However, the clinical use of recombinant TRAIL, 
have been hampered by its short half-life, unstable property 
and endogenic resistance to apoptosis in vivo [3].  
Recently, an increasing number of studies have 
demonstrated that directly targeting primary tumor 
masses or even metastatic lesions by genetically modified 
mesenchymal stem cells (MSCs) with therapeutic agents 
could be a promising therapeutic approach [4]. Therefore, 
one strategy to overcome this challenge is to genetically 
modify TRAIL in MSCs. MSCs have been demonstrated 
to be a promising vehicle for delivering therapeutic agents 
to tumor tissues because of its tumor tropism [5]. It has 
partially counteracted the shortcoming of TRAIL treatment 
[6 ]. Meanwhile, Current clinical trials using systemic 
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administration of TRAIL or TRAIL receptor sensitizers have 
largely been unsuccessful revealed the importance of TRAIL 
resistance, even when these targeted drugs are known to 
penetrate into tumor tissues [7-12]. This indicates that some 
inherent defects in the apoptotic program limit its utilization 
in the clinical application [13]. The defects may contribute to 
drug resistance and tumor progression and may be caused by 
deregulated expression of anti-apoptotic molecules. 
MicroRNAs (miRNAs) are evolutionarily well-conserved, 
small non-coding transcripts. Accumulating evidences 
demonstrated that miRNAs are emerging as key regulators of 
multiple pathways involved in cancer development and 
progression [14]. In recent years, a serial of miRNAs has been 
demonstrated to play important roles in negatively regulating 
TRAIL sensitivity in GBM cells [15, 16]. They impair 
TRAIL-dependent apoptosis by inhibiting the expression of 
key functional proteins. For example, miR-21 suppresses 
TRAIL sensitivity in GBM cells by targeting a p53 family 
member TAp63. And miR-30 inhibits TRAIL responsiveness 
through inhibition of caspase-3 activation in GBM cells [16]. 
However, even nowadays, there is no systematic screening 
for miRNA-based natural sensitizers for TRAIL sensitivity in 
GBM cells. In the current study, using a global analysis in 
TRAIL sensitive and resistant GBM cells, we identified that 
miR-7, a tumor suppressor microRNA could be a potential 
sensitizer for TRAIL sensitivity in GBM cells. Our gain and 
loss of function experiments validated that overexpression of 
miR-7 increases TRAIL sensitivity in resistant GBM cells, 
whereas miR-7 inhibition significantly decreases 
responsiveness of GBM cells to TRAIL treatment. Moreover, 
we also provided evidences that this function is not restricted 
to GBM, but also present in other tumor types such as 
hepatocellular carcinoma (HCC) cells. As a brain enriched 
miRNA, we suppose that miR-7 could be a multifaceted 
molecular regulating multiple signaling pathways under 
physiological and pathological situations. Here, we 
demonstrated that miR-7 is a natural sensitizer for TRAIL 
sensitivity in GBM cells. 
When we wondered to know the detailed molecular 
mechanism of miR-7’s effect on TRAIL sensitivity in GBM 
cells, we found that an IAP family member XIAP is a direct 
target gene of miR-7. XIAP blocks apoptosis downstream of 
mitochondria by binding to and inhibiting caspase-3 and 
caspase-9 [17, 18]. An increasing number of clinical trials of 
XIAP targeted cancer treatment further confirmed that XIAP 
is a node molecule regulating cell death sensitivity [19, 20]. 
Moreover, the results of our gene silencing and rescue 
experiments support the opinion that miR-7-XIAP axis 
contributes to TRAIL sensitivity in GBM and other tumor 
types.  
In recent years, a growing number of evidences 
demonstrated that exosomes could be a naturally delivery 
tool to transfer miRNAs for cell-cell communication [21-23]. 
All reports support that cells can secrete miRNAs and deliver 
them into recipient cells where the exogenous miRNAs can 
regulate target gene expression and recipient cell function. In 
our study, we speculated that enforced expression of 
exogenous miR-7 in sTRAIL-overexpressed mesenchymal 
stem cells may increase apoptosis and suppressed tumor 
growth in an exosome dependent manner. Finally, our 
Figure 1. Synergistic effect of TRAIL and miR-7 co-expressing MSCs for cancer killing. TRAIL-expressing MSCs 
were established by lentiviral expression system. The cells were transiently transfected with miR-7 mimics. TRAIL/miR-7 
co-expressing MSCs were intravenously injected into tumor-burdened animals. They were recruited to local tumor. TRAIL is 
secreted and induces cancer cell apoptosis. MiR-7 transfers to cancer cells from MSCs via exosomes and enhances TRAIL 
sensitivity by reducing XIAP expression in tumor tissues. 
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proof-of-principle study showed that therapeutic miR-7 
produced in MSCs and loaded into extracellular exosomes 
could lead to synergistic antitumor efficacy with sTRAIL by 
inhibiting its target gene XIAP.  
In summary, we screened and identified that miR-7 is a 
bona fide sensitizer for TRAIL sensitivity in GBM and also 
other tumor types. The mechanistic study showed that 
miR-7-XIAP axis plays a critical role for TRAIL sensitivity 
in cancers. As shown in Figure 1, we sought to evaluate the 
combined effect of exosome-transferred miR-7 and 
MSCs-mediated soluble TRAIL (sTRAIL) delivery on tumor 
growth in vitro and in vivo. We confirmed here that 
combining miR-7 overexpression with sTRAIL leads to 
synergistic tumor suppression effect in vitro and in vivo. Our 
study provides evidence for the co-delivery of sTRAIL and 
tumor suppressor miRNAs by MSCs to tumor tissues via 
exosomes and may highlight a novel therapeutic strategy for 
GBM. 
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